Close Menu

NEW YORK (360Dx) – Taiwanese pharma firm TaiRx has established a US-based corporation to commercialize a drug and companion diagnostic targeting the nodal protein, which has been linked to aggressiveness and drug resistance in a variety of cancers.

Formed in August, the Rockville, Maryland-based company, called TaiRx US, is a joint venture between TaiRx and BioHealth Innovation (BHI), a public-private partnership organization that promotes the development of biotech and health businesses in the Washington DC region.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.